Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma

Ciltacabtagene autoleucel (also known as cilta-cel) is a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) on the surface of cancer cells in B cell malignancies, such as multiple myeloma (MM). It is a second-generation CAR that is outfitted with an ectodoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Chekol Abebe, Endeshaw, Yibeltal Shiferaw, Mestet, Tadele Admasu, Fitalew, Asmamaw Dejenie, Tadesse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479060/
https://www.ncbi.nlm.nih.gov/pubmed/36119032
http://dx.doi.org/10.3389/fimmu.2022.991092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479060/
https://www.ncbi.nlm.nih.gov/pubmed/36119032
http://dx.doi.org/10.3389/fimmu.2022.991092

Ejemplares similares